Stocks · News reference
Jazz Pharmaceuticals Announces Private Offering Of $1B Of Exchangeable Senior Notes Due 2032; Expects To Repurchase Up To $225M Of Stock From Note Buyers In Privately Negotiated Transactions
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditions
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 26, 2026, 11:08 AM
- Checked
- Aug 26, 2026, 11:08 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $300
Deutsche Bank analyst David Hoang maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $287 to $300.
Read original at benzingaMorgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.
Read original at benzingaThese Analysts Increase Their Forecasts On Jazz Pharmaceuticals
FDA approves JAZZ's Ziihera-containing combination regimens for HER2-positive gastroesophageal adenocarcinoma. JAZZ stock drops 0.8% to $258.14. Analysts raise price targets to $310 and $281 in response to positive earnings. Considering buying JAZZ? Here's what analysts say.
Read original at benzinga